Biotech Stock News: Amgen Set for Big Things in the Near Future

Biotechnology Stockmarket Biotech

Amgen Inc (AMGN) received encouraging news from the FDA as the regulatory body granted priority review status to the New Drug Application (NDA) for its pipeline candidate, ivabradine. Amgen is looking to get ivabradine approved for the treatment of chronic heart failure.

Te FDA grants priority review status to candidates which have the potential to bring significant improvements in terms of safety or effectiveness in the treatment, diagnosis or prevention of serious diseases when compared to currently available therapies. Priority review means the FDA will provide a response on the approval status of the candidate within six months of receiving the regulatory application.

The NDA was submitted by Amgen in July this year. This means a response from the FDA should be out early next year.

Biotech Stock News

According to the press release issued by Amgen, heart failure affects nearly 26 million people across the world including 5.1 million in the U.S. alone. Approximately 2.5 million people in the U.S. die within five years of diagnosis. The approval of ivabradine will provide significant benefit to the eligible patient population in the U.S.

Amgen also has fast track designation for ivabradine.

Amgen has a licensing agreement with Servier, a privately-run French research-based pharmaceutical company, for ivabradine under which Amgen will commercialize ivabradine in the U.S. Ivabradine is currently approved in the EU under the trade name Procoralan, for stable angina and chronic heart failure in patients with elevated heart rates.

Biotech News Video

Watch this video for more “Biotech” news.

[grabpress_video guid=62c4a5774f3266964d11a28ba963bd81ebc72453 embed_id=2151917]

Biotech Financial News

It was an eventful week on the pipeline front for Amgen (AMGN). The company said that its chronic heart failure drug, ivabradine, will be reviewed on a priority basis by the FDA. Amgen also submitted its PCSK9 inhibitor, evolocumab, for FDA approval. Evolocumab is one of the most important candidates in Amgen’s pipeline and represents huge commercial potential, once approved and launched.

Thanks for visiting the website. Be sure to catch all BioTech financial news, bookmark us and check all the videos and news articles regarding Biotech business news.

Signup for free to be the first to receive exclusive free links. Now in your mailbox!
Join over 15,000 subscribers
Send me links

Your information will not be shared to anyone